Literature DB >> 21349709

Exploring new near-infrared fluorescent disulfide-based cyclic RGD peptide analogs for potential integrin-targeted optical imaging.

Yunpeng Ye1, Baogang Xu, Gregory V Nikiforovich, Sharon Bloch, Samuel Achilefu.   

Abstract

We synthesized disulfide-based cyclic RGD pentapeptides bearing a near-infrared fluorescent dye (cypate), represented by cypate-c(CRGDC) (1) for integrin-targeted optical imaging. These compounds were compared with the traditional lactam-based cyclic RGD counterpart, cypate-c(RGDfK) (2). Molecular modeling suggests that the binding affinity of 2 to integrin α(v)β(3) is an order of magnitude higher than that of 1. This was confirmed experimentally, which further showed that substitution of Gly with Pro, Val and Tyr in 1 remarkably hampered the α(v)β(3) binding. Interestingly, cell microscopy with A549 cells showed that 1 exhibited higher cellular staining than 2. These results indicate that factors other than receptor binding affinity to α(v)β(3) dimeric proteins mediate cellular uptake. Consequently, 1 and its analogs may serve as valuable molecular probes for investigating the selectivity and specificity of integrin targeting by optical imaging.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21349709      PMCID: PMC3056947          DOI: 10.1016/j.bmcl.2011.01.133

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  46 in total

1.  Integrin alphaIIbbeta3:ligand interactions are linked to binding-site remodeling.

Authors:  Roy R Hantgan; Mary C Stahle; John H Connor; David A Horita; Mattia Rocco; Mary A McLane; Sergiy Yakovlev; Leonid Medved
Journal:  Protein Sci       Date:  2006-08       Impact factor: 6.725

Review 2.  Design and chemical synthesis of integrin ligands.

Authors:  Dominik Heckmann; Horst Kessler
Journal:  Methods Enzymol       Date:  2007       Impact factor: 1.600

Review 3.  Imaging of integrin alphavbeta3 expression.

Authors:  Ambros J Beer; Markus Schwaiger
Journal:  Cancer Metastasis Rev       Date:  2008-12       Impact factor: 9.264

4.  Noninvasive optical imaging of ovarian metastases using Cy5-labeled RAFT-c(-RGDfK-)4.

Authors:  Zhao-Hui Jin; Veronique Josserand; Jesus Razkin; Elisabeth Garanger; Didier Boturyn; Marie-Christine Favrot; Pascal Dumy; Jean-Luc Coll
Journal:  Mol Imaging       Date:  2006-07       Impact factor: 4.488

5.  99mTc-NC100692--a tracer for imaging vitronectin receptors associated with angiogenesis: a preclinical investigation.

Authors:  David Edwards; Paul Jones; Helena Haramis; Mark Battle; Rochelle Lear; D Jon Barnett; Catherine Edwards; Hazel Crawford; Andrew Black; Vanessa Godden
Journal:  Nucl Med Biol       Date:  2008-04       Impact factor: 2.408

6.  Engineered knottin peptides: a new class of agents for imaging integrin expression in living subjects.

Authors:  Richard H Kimura; Zhen Cheng; Sanjiv Sam Gambhir; Jennifer R Cochran
Journal:  Cancer Res       Date:  2009-03-10       Impact factor: 12.701

7.  Novel near-infrared fluorescent integrin-targeted DFO analogue.

Authors:  Yunpeng Ye; Sharon Bloch; Baogang Xu; Samuel Achilefu
Journal:  Bioconjug Chem       Date:  2007-11-27       Impact factor: 4.774

8.  Dual-function probe for PET and near-infrared fluorescence imaging of tumor vasculature.

Authors:  Weibo Cai; Kai Chen; Zi-Bo Li; Sanjiv S Gambhir; Xiaoyuan Chen
Journal:  J Nucl Med       Date:  2007-10-17       Impact factor: 10.057

9.  Conjugated platinum(IV)-peptide complexes for targeting angiogenic tumor vasculature.

Authors:  Sumitra Mukhopadhyay; Carmen M Barnés; Ariel Haskel; Sarah M Short; Katie R Barnes; Stephen J Lippard
Journal:  Bioconjug Chem       Date:  2007-09-11       Impact factor: 4.774

10.  Stimulation of tumor growth and angiogenesis by low concentrations of RGD-mimetic integrin inhibitors.

Authors:  Andrew R Reynolds; Ian R Hart; Alan R Watson; Jonathan C Welti; Rita G Silva; Stephen D Robinson; Georges Da Violante; Morgane Gourlaouen; Mishal Salih; Matt C Jones; Dylan T Jones; Garry Saunders; Vassiliki Kostourou; Françoise Perron-Sierra; Jim C Norman; Gordon C Tucker; Kairbaan M Hodivala-Dilke
Journal:  Nat Med       Date:  2009-03-22       Impact factor: 53.440

View more
  6 in total

1.  Near-infrared fluorescent divalent RGD ligand for integrin αvβ₃-targeted optical imaging.

Authors:  Yunpeng Ye; Walter Akers; Baogang Xu; Sharon Bloch; Charles Odonkor; Samuel Achilefu
Journal:  Bioorg Med Chem Lett       Date:  2012-07-20       Impact factor: 2.823

2.  Targeted non-covalent self-assembled nanoparticles based on human serum albumin.

Authors:  Anton Bunschoten; Tessa Buckle; Joeri Kuil; Gary D Luker; Kathryn E Luker; Omgo E Nieweg; Fijs W B van Leeuwen
Journal:  Biomaterials       Date:  2011-10-22       Impact factor: 12.479

3.  Tailored near-infrared contrast agents for image guided surgery.

Authors:  Costyl N Njiojob; Eric A Owens; Lakshminarayana Narayana; Hoon Hyun; Hak Soo Choi; Maged Henary
Journal:  J Med Chem       Date:  2015-03-04       Impact factor: 7.446

4.  Tunable ultrasmall visible-to-extended near-infrared emitting silver sulfide quantum dots for integrin-targeted cancer imaging.

Authors:  Rui Tang; Jianpeng Xue; Baogang Xu; Duanwen Shen; Gail P Sudlow; Samuel Achilefu
Journal:  ACS Nano       Date:  2015-01-07       Impact factor: 15.881

5.  Tumor-penetrating iRGD peptide inhibits metastasis.

Authors:  Kazuki N Sugahara; Gary B Braun; Tatiana Hurtado de Mendoza; Venkata Ramana Kotamraju; Randall P French; Andrew M Lowy; Tambet Teesalu; Erkki Ruoslahti
Journal:  Mol Cancer Ther       Date:  2014-11-12       Impact factor: 6.261

6.  Emerging putative biomarkers: the role of alpha 2 and 6 integrins in susceptibility, treatment, and prognosis.

Authors:  James R Marthick; Joanne L Dickinson
Journal:  Prostate Cancer       Date:  2012-07-31
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.